Antifungal prophylaxis in high-risk patients with hematologic malignancy:a comparison of practice with guidelines in Türkiye
Turkish Journal of Medical Sciences · 18.02.2025 · 55 (1) · 52-64
DOI: 10.55730/1300-0144.5942 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 18.02.2025. Verfasst von Özlem Güzel Tunçcan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Faculty of Medicine, Gazi University, Ankara, Turkiye. Hauptthemen laut MEDLINE: Antifungal Agents, Hematologic Neoplasms, Practice Guidelines as Topic, Mycoses. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: Primary antifungal prophylaxis (AFP) is recommended by guidelines as the gold standard for patients with hematologic malignancies. This study aimed to investigate the level of knowledge and translation of guideline recommendations into real-life setting among physicians in Türkiye.Materials and methods: In this prospective, observational study, the physicians’ knowledge of ΑFP guideline recommendations in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) undergoing first remission-induction (Group I), and graft-versus-host-disease (GvHD) after allogeneic stem cell transplant (Group II), was compared with clinical practice via 11-item multiple-choice questionnaire evaluating the timing and patients in whom AFP was initiated, with AFP duration and drugs used.
Results
The mean age was 48.3 years and 79% had AML/MDS. AFP was initiated in 75.3% of Group I patients on the first day of induction chemotherapy before baseline and in 26.2% of Group II patients at baseline. In 98.8% of AML/MDS patients, AFP was planned to be continued until recovery from neutropenia and complete remission, whereas during immunosuppression in Group II. The median (IQR) duration of AFP was 0.8 (0.5 - 1.9) and 5.5 (2.4 - 8.1) months in Group I and II, respectively. Breakthrough invasive fungal infections (bIFIs) were observed in 35.8% and 14.3% of Group I and II, respectively.The mean survey scores were 8.5 ± 2.3 points in AML/MDS, and 9.9 ± 3.2 in GvHD patient groups. Most of the sites adhered to European Conference on Infections in Leukemia (ECIL) Guideline (80.6%), followed by Infectious Diseases Society of America, Fever and Neutropenia Guideline (IDSA) recommendations (51.6%). Posaconazole was the drug of choice in both groups (96.8% in Group I vs. 71% in Groups II).
Conclusion
The data indicate an inconsistency between real-life clinical practice and guideline recommendations for primary AFP and bIFI management in high-risk patients with hematologic malignancies in Türkiye.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Faculty of Medicine, Gazi University, Ankara, Turkiye.
- Division of Hematology, Department of Internal Medicine, Medical Park Hospital, İzmir, Turkiye.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Başkent University, Adana, Turkiye.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Ege University, İzmir, Turkiye.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Turkiye.
ORCID-Profile: Özlem Güzel Tunçcan, Seçkin Çağirgan, Hakan Özdoğu, Sinem Civriz Bozdağ, Filiz Vural, Mustafa Pehlivan, Hüseyin Saffet Beköz, Yasemin Esen, Tuba Koç, Petek Gilik, Esin Şenol
Zitieren
APA
Güzel Tunçcan, Ö., Çağirgan, S., Özdoğu, H., Civriz Bozdağ, S., Vural, F., Pehlivan, M., Beköz, H. S., Esen, Y., Koç, T., Gilik, P., & Şenol, E. (2025). Antifungal prophylaxis in high-risk patients with hematologic malignancy:a comparison of practice with guidelines in Türkiye. Turkish Journal of Medical Sciences, 55(1), 52-64. https://doi.org/10.55730/1300-0144.5942
Vancouver
Güzel Tunçcan Ö, Çağirgan S, Özdoğu H, Civriz Bozdağ S, Vural F, Pehlivan M, et al. Antifungal prophylaxis in high-risk patients with hematologic malignancy:a comparison of practice with guidelines in Türkiye. Turkish Journal of Medical Sciences. 2025;55(1):52-64. doi:10.55730/1300-0144.5942
BibTeX
@article{GzelTuncan2025,
author = {Güzel Tunçcan, Özlem and Çağirgan, Seçkin and Özdoğu, Hakan and Civriz Bozdağ, Sinem and Vural, Filiz and Pehlivan, Mustafa and Beköz, Hüseyin Saffet and Esen, Yasemin and Koç, Tuba and Gilik, Petek and Şenol, Esin},
title = {Antifungal prophylaxis in high-risk patients with hematologic malignancy:a comparison of practice with guidelines in Türkiye},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {1},
pages = {52--64},
doi = {10.55730/1300-0144.5942}
}
EUVIMED